Luminex Co. (NASDAQ:LMNX) Director G Walter Loewenbaum II sold 39,456 shares of Luminex stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $20.40, for a total transaction of $804,902.40. Following the completion of the transaction, the director now directly owns 651,736 shares of the company’s stock, valued at $13,295,414.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

G Walter Loewenbaum II also recently made the following trade(s):

  • On Thursday, November 16th, G Walter Loewenbaum II sold 50,000 shares of Luminex stock. The stock was sold at an average price of $21.79, for a total transaction of $1,089,500.00.

Luminex Co. (LMNX) opened at $20.37 on Friday. Luminex Co. has a twelve month low of $17.68 and a twelve month high of $22.42. The firm has a market cap of $904.00, a P/E ratio of 35.38, a PEG ratio of 2.58 and a beta of 0.19.

Luminex (NASDAQ:LMNX) last released its quarterly earnings data on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.06. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The firm had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $74.38 million. During the same period in the previous year, the company earned $0.21 earnings per share. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. analysts anticipate that Luminex Co. will post 0.49 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Stockholders of record on Friday, December 22nd will be issued a dividend of $0.06 per share. The ex-dividend date is Thursday, December 21st. This represents a $0.24 annualized dividend and a dividend yield of 1.18%. Luminex’s payout ratio is 36.36%.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pinebridge Investments L.P. raised its holdings in shares of Luminex by 8.3% during the second quarter. Pinebridge Investments L.P. now owns 5,266 shares of the medical instruments supplier’s stock valued at $111,000 after purchasing an additional 405 shares during the last quarter. First Quadrant L P CA purchased a new position in shares of Luminex during the third quarter valued at approximately $173,000. Sei Investments Co. raised its holdings in shares of Luminex by 38.7% during the second quarter. Sei Investments Co. now owns 8,245 shares of the medical instruments supplier’s stock valued at $174,000 after purchasing an additional 2,299 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Luminex by 37.4% during the second quarter. SG Americas Securities LLC now owns 9,726 shares of the medical instruments supplier’s stock valued at $205,000 after purchasing an additional 2,649 shares during the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new position in shares of Luminex during the third quarter valued at approximately $254,000. 79.19% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have issued reports on LMNX shares. Zacks Investment Research raised shares of Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 target price for the company in a report on Thursday, August 24th. ValuEngine raised shares of Luminex from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Jefferies Group reaffirmed a “hold” rating and issued a $21.00 target price on shares of Luminex in a report on Friday, October 20th. TheStreet raised shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Finally, BidaskClub cut shares of Luminex from a “hold” rating to a “sell” rating in a report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $20.00.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/15/g-walter-loewenbaum-ii-sells-39456-shares-of-luminex-co-lmnx-stock.html.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.

Insider Buying and Selling by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Stock Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related stocks with our FREE daily email newsletter.